


# Etude et Suivi des POlyarthrites Indifférenciées Récentes

## Study & follow-up of undifferentiated early arthritis A french multicenter cohort



la médecine fondée sur les preuves.

## **Primary objective**

**Multicenter french cohort of early arthritis**

**for studies on:**

- Diagnosis**
- Prognosis**
- Economic evaluation**
- Pathogenesis**
- Therapeutic evaluation**

## **Inclusion criteria**

- **Early arthritis with possible or certain RA**
- **At least 2 swollen joints**
- **> 6 weeks, < 6 months**
- **No previous DMARD**
- **No previous steroids**
- **Signed consent**
- **Social security**

## Exclusion criteria

- **Age < 18, > 70**
- **Pregnancy**
- **Early arthritis with diagnosis other than RA  
OR with features incompatible with RA**

## **Specific objectives**

### **1. *Diagnosis***

**Best combination of clinical, biologic, imaging and immunogenetic elements for diagnosis**

### **2. *Prognosis***

**Early prognosis, determining « high-risk » profiles**

### **3. *Economics***

**Direct and indirect costs.**

## **Specific objectives**

### ***4. Pathogeny***

**Constitution of a bank of serum, DNA, blood and synovial cells and synovial tissue for multiple studies: genomics, micro-arrays, auto-antibodies...**

### ***5. Comorbidity and disability***

### ***6. Observation of rare events: IRAD project.***

## **Method**


- **Longitudinal prospective study: follow-up > 10 years**
- **800 patients**
- **Inclusion period 18 months**
- **Follow-up: inclusion, M6, M12, M18, M24 then once a year**
- **Inclusion started November 14, 2002.**

## **Recruitment**

- **14 regional centers with a network of private practice rheumatologists**
  - **2 biology coordinating centers**
  - **1 national coordinating center**
  - **National project promoted by the French Rheumatology Society (SFR)**
- partnered by Merck (MSD) and INSERM**
- also supported by AMGEN and ABBOTT.**



# Etude et Suivi des POlyarthrites Indifférenciées Récentes



## Collected data


- **At each visit:**
  - clinical,
  - HAQ, SF 36...
  - Economic questionnaire,
  - standard biology,
  - Serum and urine samples,
  - hands and feet X Rays
- **At baseline:**

Blood, DNA, blood cells, synovial cells and/or synovial tissue
- **MRI/ ultrasonography protocols**

# Etude et Suivi des POlyarthrites Indifférenciées Récentes

## Inclusions


Nb of inclusion



# Etude et Suivi des POlyarthrites Indifférenciées Récentes

Nombre de patients screenés et inclus dans chaque centre

Nb de patients



centres

## **Therapeutic trials**

- **Therapeutic decisions will be taken by the treating private practitioners; recruitment centers will not interfere in therapeutic choices.**
- **BUT therapeutic trials are possible if accepted by the rheumatologists and the patients.**

## **Scientific steering committee**

- **CHU Brest**
  - **CHU Montpellier**
  - **CHU Nancy**
  - **CHU Paris Bichat**
  - **CHU Paris Cochin**
  - **CHU Paris Pitié-Salpêtrière**
  - **CHU Rouen**
  - **CHU Strasbourg**
  - **CHU Toulouse**
  - **MSD laboratory**
- Prof. Alain SARAUX**  
**Prof. Bernard COMBE**  
**Prof. Francis GUILLEMIN**  
**Prof. Philippe RAVAUD**  
**Prof. Maxime DOUGADOS**  
**Dr. Bruno FAUTREL**  
**Prof. Xavier LE LOËT**  
**Prof. Jean SIBILIA**  
**Prof. Alain CANTAGREL**  
**Dr. Isabelle LOGEART**